iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
March 27, 2024 07:00 ET
|
iBio, Inc.
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover,...
iBio Announces $15.0 Million Private Placement
March 26, 2024 19:35 ET
|
iBio, Inc.
– Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an...
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
February 26, 2024 07:45 ET
|
iBio, Inc.
– Deal includes $1 million upfront and potential future milestone payments – – iBio’s proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – ...
iBio Announces Participation in 23rd Annual PepTalk Conference
January 16, 2024 08:15 ET
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that...
iBio Amends and Extends Maturity of Credit Agreement
December 26, 2023 07:15 ET
|
iBio, Inc.
– Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) --...
iBio, Inc. Announces Pricing of $4.5 Million Public Offering
December 05, 2023 08:00 ET
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of...
iBio Announces Reverse Stock Split
November 27, 2023 17:20 ET
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of...
iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
November 01, 2023 08:24 ET
|
iBio, Inc.
- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action - BRYAN, Texas and SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- iBio,...
iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
October 10, 2023 08:00 ET
|
iBio, Inc.
- VP of Platform Technologies, Matt Greving, to present data on enhancing T-cell engagers using machine-learning guided epitope steering and mammalian display antibody libraries - BRYAN, Texas...
iBio Explains Recent Filing of Registration Statement
October 02, 2023 06:45 ET
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- In response to investor inquiries received about the post-effective amendment to its Form S-3 on Form S-1 (the “Post-Effective...